Table 2 The baseline characteristics in the nafamostat mesilate and the control groups after matching
From: The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
Nafmostat mesilate (n = 201) | Control (n = 106) | Total (N = 307) | P value | |
|---|---|---|---|---|
Age, y, median (range) | 68 (55–75) | 65 (52–73) | 66 (54–75) | 0.202 |
Male (%) | 74 (36.8) | 47 (44.3) | 121 (39.4) | 0.186 |
History of AP (%) | 3 (1.5) | 0 | 3 (1.0) | |
SOD (%) | 2 (1.0) | 0 | 2 (0.7) | |
Purpose of ERCP (%) | ||||
Choledocholithiasis | 120 (59.7) | 56 (52.8) | 176 (57.3) | 0.401 |
Malignant biliary stricture | 67 (33.3) | 42 (39.6) | 109 (35.5) | 0.260 |
Benign biliary stricture | 11 (5.5) | 4 (1.3) | 15 (4.9) | 0.437 |
Biliary leakage | 0 | 1 (0.9) | 1 (0.3) | |
Pancreatic cyst | 1 (0.5) | 2 (1.9) | 3 (1.0) | 0.611 |
Other indicationa | 2 (1.0) | 1 (0.9) | 3 (1.0) | 0.646 |
Procedures (%) | ||||
Difficult cannulation | 115 (57.2) | 50 (47.2) | 165 (53.7) | 1.000 |
P-duct manipulation | 69 (34.3) | 36 (34.0) | 105 (34.2) | 0.229 |
Precut EST | 70 (34.8) | 34 (32.1) | 104 (33.9) | 0.729 |
Pancreatic EST | 44 (21.9) | 17 (16.0) | 61 (19.9) | 1.000 |
EPBD | 21 (10.4%) | 14 (13.2) | 35 (11.4) | 0.893 |
ERPD | 43 (21.4%) | 15 (14.2) | 58 (18.9) | 1.000 |